+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Blood Screening Market Size, Share & Trends Analysis Report By Technology (NAT, ELISA, CLIA, NGS, Western Blotting), By Product (Reagents, Instruments), And Segment Forecasts, 2018 - 2025

  • ID: 4751773
  • Report
  • Region: Europe
  • 64 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Agilent Technologies
  • Danaher
  • Grifols, S.A.
  • Roche Diagnostics
  • Siemens Healthcare GmBH
  • MORE
The Europe blood screening market size is expected to reach USD 1.17 billion by 2025 according to a new report. The market is expected to record a CAGR of 7.7% during the forecast period. Increasing number of blood transfusion processes performed along with stringent regulations in Europe mandating screening tests, such as NAT for testing HIV, HBV, and HCV, is contributing to the market growth.

Moreover, growth in the overall number of complex surgeries that require a large amount of blood and blood products along with rising cases of road accidents is expected to drive the market further. Additionally, import of products through contract agreements and development in the product technology by manufacturers of blood screening reagents and instruments are contributing to market expansion in the region.

For example, DiaSystem Scandinavia AB signed a distribution agreement with SNIBE, an Asian immunology test producer that focuses on immunoassay analyzers based on CLIA technology. DiaSystem specializes in the production and supply of reagents used in chemistry and immunoturbidimetry. This agreement has provided the former company with automated chemiluminescence instrument delivering a complete analytical system in areas, such as thyroid, renal function, hepatitis, and hepatic fibrosis.

Further key findings from the study suggest:
  • NAT led the technology segment in 2017 owing to a regulatory obligation for mandatory NAT screening for all blood donations.
  • On the basis of product, reagents led the Europe blood screening market in 2017
  • Germany held a majority of the market share in 2017 due to large number of blood donors.
  • Moreover, stringent regulations in the country for screening of donations also contributed to its growth. The Paul-Ehrlich-Institut, a medical regulatory body in Germany, mandates NAT testing for HCV and HIV for all blood donations.
  • Roche Diagnostics; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Grifols, S.A.; Becton, Dickinson and Company; Agilent Technologies; Thermo Fisher Scientific, Inc.; and Danaher Corp. are some of the key companies operating in this market.


Please Note: This report will be delivered within 48 hours of ordering.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Agilent Technologies
  • Danaher
  • Grifols, S.A.
  • Roche Diagnostics
  • Siemens Healthcare GmBH
  • MORE
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 List to Data Sources

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Europe Blood Screening Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Europe Blood Screening Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Growing demand for blood for transfusion
3.2.1.2 Stringent Government regulations
3.2.2 Market RESTRAINTS Analysis
3.2.2.1 Insufficient blood donations
3.2.2.2 High operating cost of NAT
3.2.3 Penetration & Growth Prospects Mapping
3.2.4 Europe Blood Screening Market - PESTLE Analysis
3.2.5 Industry Analysis - Porter’s
3.3 List of Diagnostic Centres in Europe
3.4 Pricing Analysis

Chapter 4 Europe Blood Screening Market: Technology Estimates & Trend Analysis
4.1 Europe Blood Screening Market: Technology Movement Analysis
4.2 Nucleic Acid Amplification Test (NAT)
4.2.1 Europe NAT market Estimates and Forecasts, 2014 - 2025 (USD Million)
4.3 Enzyme-Linked Immunosorbent Assay (ELISA)
4.3.1 Europe ELISA market estimates and forecasts, 2014 - 2025 (USD Million))
4.4 Chemiluminescence Immunoassay (CLIA)
4.4.1 Europe CLIA market estimates and forecasts, 2014 - 2025 (USD Million)
4.5 Next-Generation Sequencing (NGS)
4.5.1 Europe NGS market estimates and forecasts, 2014 - 2025 (USD Million)
4.6 Western Blotting
4.6.1 Europe western blotting market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 5 Europe Blood Screening Market: Product Estimates & Trend Analysis
5.1 Europe Blood Screening Market: Product Movement Analysis
5.2 Reagents
5.2.1 Europe reagents market estimates and forecasts, 2014 - 2025 (USD Million)
5.3 Instruments
5.3.1 Europe instruments market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 6 Europe Blood Screening Market: Regional Estimates & Trend Analysis, by Technology & Products
6.1 Europe Blood Screening Market: Regional Movement Analysis, 2017 & 2025, USD Million
6.2 Europe
6.2.1 Europe blood screening market estimates and forecasts, 2014 - 2025 (USD Million)
6.2.2 U.K.
6.2.2.1 U.K. blood screening market estimates and forecasts, 2014 - 2025 (USD Million)
6.2.3 Germany
6.2.3.1 Germany blood screening market estimates and forecasts, 2014 - 2025 (USD Million)
6.2.4 France
6.2.4.1 France blood screening market estimates and forecasts, 2014 - 2025 (USD Million)
6.2.5 Italy
6.2.5.1 Italy blood screening market estimates and forecasts, 2014 - 2025 (USD Million)
6.2.6 SPAIN
6.2.6.1 Spain blood screening market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape
7.1 Strategic Framework
7.2 Europe Blood Screening Market: Market Position Analysis (Based on Application, Product Benchmarking, Regional Presence, and Recent Updates)
7.3 Company Profiles
7.3.1 Roche Diagnostics
7.3.1.1 Company Overview
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Bio-Rad Laboratories, Inc.
7.3.2.1 Company Overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 Siemens Healthcare GmBH
7.3.3.1 Company Overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Grifols, S.A.
7.3.4.1 Company Overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 Becton, Dickinson and Company
7.3.5.1 Company Overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 Agilent Technologies
7.3.6.1 Company Overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.7 Thermo Fisher Scientific, Inc.
7.3.7.1 Company Overview
7.3.7.2 Financial performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.8 Danaher
7.3.8.1 Company Overview
7.3.8.2 Financial performance
7.3.8.3 Product benchmarking
7.3.8.4 Strategic initiatives
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Roche Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthcare GmBH
  • Grifols, S.A.
  • Becton, Dickinson and Company
  • Agilent Technologies
  • Thermo Fisher Scientific, Inc.
  • Danaher
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4751773
Adroll
adroll